Tradestie Institutional Equity Comparison Engine

PTN vs MBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PTN Overall Edge

PTN Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Palatin Technologies, Inc. (PTN) driven by superior Valuation, Momentum & Technical while MBIO counters with relative strength in Growth & Margin. Fundamentally, PTN trades at 42.9x Forward P/E with -65.7% operating margin (-80.1% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PTN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PTN
PTN 42.9x vs MBIO N/M Fwd P/E
Growth & Margin Winner MBIO
Op Margin -65.7% vs 0.0% ยท YoY -80.1% vs +0.0%
Momentum & Technical Winner PTN
1Y -43.3% vs -67.4% ยท 52W Pos 6% vs 4%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
1M Return +1.74%
1Y Return -43.29%
Forward P/E 42.9x
Unified AI Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
1M Return +4.86%
1Y Return -67.38%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PTN -43.29% MBIO -67.38% Spread: +24.09 pp (PTN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
PTN TTM Op. Margin: -65.7% MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PTN vs MBIO. Trailing 12-month operating profitability (PTN -65.7% vs MBIO 0.0%) and valuation multiples (PTN 42.9x vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PTN (3) vs MBIO (6)
Institutional Metric PTN MBIO Criterion Row Winner
Market Capitalization Scale $11.1M $3.2M Larger Scale Tie
Trailing P/E Ratio Valuation 42.9x N/M Lower Multiple PTN
Forward P/E Ratio Valuation 42.9x N/M Lower Multiple PTN
Revenue Growth (YoY) Growth -80.1% +0.0% Higher Growth MBIO
Operating Margin (TTM) Profitability -65.7% 0.0% Higher Margin MBIO
Net Profit Margin Profitability -63.5% 0.0% Higher Margin MBIO
Return on Equity (ROE) Capital Efficiency -877.5% -43.1% Higher ROE MBIO
52-Week Range Position Momentum 6% ($5โ€“$31) 4% ($0โ€“$1) Stronger Trend PTN
Beta / 30D Volatility Risk Regime 0.87ฮฒ ยท 106% Vol 0.66ฮฒ ยท 86% Vol Lower Realized Risk MBIO
Unified Institutional Score Composite Signal 31.5 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite MBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PTN vs MBIO Buy Guide
PTN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PTN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PTN nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.